info@cymabay.com
(917) 877-2194
Home
About
Overview
Management Team
Board of Directors
Careers
Pipeline
Overview
Seladelpar
Arhalofenate
Additional Programs
Collaborations
News & Events
Press Releases
Upcoming Events
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2018
2017
2016
2015
2014
2013
2012
2011
2010
19
May
CymaBay Therapeutics to Present at UBS Global Healthcare Conference
11
May
CymaBay Reports First Quarter 2016 Financial Results
2
May
CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11
29
Mar
CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results
28
Mar
CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors
28
Mar
CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology
22
Mar
CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors
21
Mar
CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29
17
Mar
CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
3
Mar
CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March
<< Previous
1...
2
3
4
5
6
7
8
9
10
11
...13
Next >>
Show All
Scroll
